Syndax Pharmaceuticals struggles with competitive pressures and market skepticism despite promising drugs and strong cash position. Read more on SNDX here.

RBC Capital Markets adjusted its stance on Intra-Cellular Therapies shares, downgrading the biopharmaceutical company from Outperform to Sector Perform. The firm, however, raised its price target on ...

CoStar Group Inc (CSGP) stock saw a modest uptick, ending the day at $73.85 which represents a slight increase of $0.43 or 0.59% from the prior close of $73.42. The stock opened at $75.06 and touched ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.08 which represents a slight increase of $0.11 or 1.58% from the prior close of $6.97. The stock opened at $7.02 and ...

RBC Capital Markets adjusted its stance on CF Industries Holdings Inc. (NYSE:CF), downgrading the stock from 'Outperform' to ...

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on uniQure (QURE – Research Report), with a price target of ...

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target ...

TipRanks’ analyst ranking service reveals the top 10 U.S. analysts whose ratings were the most successful between October ...

Higher medical expenses combined with stricter government payment policies have pressured UnitedHealth's earnings for more ...

The catastrophic wildfires in Los Angeles County have rocked the stock of Edison International, the parent company of ...

The page may have been moved or deleted. You can try searching for it below, move on or ask for help.

JPMorgan, Wells Fargo, Goldman Sachs and Citi kicked off earnings season on Wednesday with their December-quarter results.